Equities Research Analysts’ Updated EPS Estimates for November 14th (ACRV, ACXP, ADUS, ALMS, ALT, ARDT, ASM, AURA, BHVN, BITF)

Equities Research Analysts’ updated eps estimates for Thursday, November 14th:

Acrivon Therapeutics (NASDAQ:ACRV) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $22.00 target price on the stock.

Acurx Pharmaceuticals (NASDAQ:ACXP) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $12.00 target price on the stock.

Addus HomeCare (NASDAQ:ADUS) had its outperform rating reissued by analysts at Royal Bank of Canada. The firm currently has a $136.00 price target on the stock.

Alumis (NASDAQ:ALMS) had its overweight rating reissued by analysts at Cantor Fitzgerald.

Altimmune (NASDAQ:ALT) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $12.00 price target on the stock.

Ardent Health Partners (NYSE:ARDT) had its outperform rating reissued by analysts at Royal Bank of Canada. They currently have a $23.00 target price on the stock.

Avino Silver & Gold Mines (NYSE:ASM) had its buy rating reaffirmed by analysts at Roth Mkm. Roth Mkm currently has a $1.80 target price on the stock, down from their previous target price of $1.90.

Avino Silver & Gold Mines (NYSE:ASM) had its buy rating reissued by analysts at Roth Mkm. Roth Mkm currently has a $1.80 price target on the stock, down from their previous price target of $1.90.

Aura Biosciences (NASDAQ:AURA) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $22.00 price target on the stock.

Biohaven (NYSE:BHVN) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $59.00 price target on the stock.

Bitfarms (NASDAQ:BITF) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $4.00 price target on the stock.

BioNTech (NASDAQ:BNTX) had its buy rating reissued by analysts at Canaccord Genuity Group Inc.. The firm currently has a $171.00 price target on the stock.

Beachbody (NYSE:BODI) had its buy rating reiterated by analysts at Roth Mkm. The firm currently has a $12.00 price target on the stock.

Boxlight (NASDAQ:BOXL) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $1.00 price target on the stock.

CalciMedica (NASDAQ:CALC) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $16.00 price target on the stock.

Clene (NASDAQ:CLNN) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $31.00 target price on the stock.

Clearside Biomedical (NASDAQ:CLSD) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $6.00 target price on the stock.

Complete Solaria (NASDAQ:CSLR) had its overweight rating reissued by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $6.00 target price on the stock.

CyberArk Software (NASDAQ:CYBR) had its buy rating reiterated by analysts at Truist Financial Co.. They currently have a $350.00 target price on the stock, up from their previous target price of $300.00.

CyberArk Software (NASDAQ:CYBR) had its overweight rating reiterated by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $335.00 target price on the stock.

Digi International (NASDAQ:DGII) had its hold rating reiterated by analysts at Craig Hallum. They currently have a $32.00 target price on the stock, up from their previous target price of $28.00.

DURECT (NASDAQ:DRRX) had its neutral rating reiterated by analysts at HC Wainwright.

Dyadic International (NASDAQ:DYAI) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $6.00 price target on the stock.

Forian (NASDAQ:FORA) had its buy rating reissued by analysts at Roth Mkm. Roth Mkm currently has a $5.00 target price on the stock.

Fulcrum Therapeutics (NASDAQ:FULC) had its sector perform rating reaffirmed by analysts at Royal Bank of Canada. The firm currently has a $4.00 target price on the stock.

Fulcrum Therapeutics (NASDAQ:FULC) had its neutral rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $4.00 price target on the stock.

Formula One Group (NASDAQ:FWONA) had its buy rating reissued by analysts at Benchmark Co.. Benchmark Co. currently has a $81.00 target price on the stock.

ESS Tech (NYSE:GWH) had its hold rating reissued by analysts at Canaccord Genuity Group Inc.. Canaccord Genuity Group Inc. currently has a $8.00 price target on the stock.

Integral Ad Science (NASDAQ:IAS) had its hold rating reiterated by analysts at Benchmark Co..

Intellicheck (NYSE:IDN) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $4.00 price target on the stock.

Immuneering (NASDAQ:IMRX) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $15.00 price target on the stock.

Loar (NYSE:LOAR) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. They currently have a $100.00 target price on the stock.

Liquidia (NASDAQ:LQDA) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $19.00 price target on the stock.

Lucid Diagnostics (NASDAQ:LUCD) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $2.50 price target on the stock.

Lucid Diagnostics (NASDAQ:LUCD) had its buy rating reiterated by analysts at Canaccord Genuity Group Inc.. Canaccord Genuity Group Inc. currently has a $3.00 price target on the stock.

Mastercard (NYSE:MA) had its outperform rating reiterated by analysts at Royal Bank of Canada. They currently have a $572.00 price target on the stock.

Seres Therapeutics (NASDAQ:MCRB) had its buy rating reiterated by analysts at Canaccord Genuity Group Inc.. They currently have a $10.00 price target on the stock.

MoonLake Immunotherapeutics (NASDAQ:MLTX) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $100.00 price target on the stock.

Topgolf Callaway Brands (NYSE:MODG) had its buy rating reissued by analysts at Roth Mkm. Roth Mkm currently has a $16.00 price target on the stock, down from their previous price target of $17.00.

Mosaic (NYSE:MOS) had its sector perform rating reaffirmed by analysts at Royal Bank of Canada. They currently have a $30.00 price target on the stock.

Marinus Pharmaceuticals (NASDAQ:MRNS) had its neutral rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $2.00 price target on the stock.

Marinus Pharmaceuticals (NASDAQ:MRNS) had its overweight rating reiterated by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $4.00 price target on the stock.

NICE (NASDAQ:NICE) had its neutral rating reiterated by analysts at Piper Sandler.

NVIDIA (NASDAQ:NVDA) had its outperform rating reissued by analysts at Wedbush. Wedbush currently has a $160.00 price target on the stock, up from their previous price target of $138.00.

OmniAb (NASDAQ:OABI) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $11.00 target price on the stock.

OmniAb (NASDAQ:OABI) had its buy rating reiterated by analysts at Benchmark Co.. The firm currently has a $8.00 price target on the stock.

Omeros (NASDAQ:OMER) had its hold rating reaffirmed by analysts at Needham & Company LLC.

Omeros (NASDAQ:OMER) had its neutral rating reiterated by analysts at Cantor Fitzgerald.

Oncolytics Biotech (NASDAQ:ONCY) had its buy rating reissued by analysts at HC Wainwright. They currently have a $5.00 price target on the stock.

OptimizeRx (NASDAQ:OPRX) had its buy rating reaffirmed by analysts at Roth Mkm. The firm currently has a $16.00 target price on the stock, down from their previous target price of $20.00.

Passage Bio (NASDAQ:PASG) had its buy rating reissued by analysts at Canaccord Genuity Group Inc.. Canaccord Genuity Group Inc. currently has a $13.00 target price on the stock.

Rigetti Computing (NASDAQ:RGTI) had its buy rating reissued by analysts at Benchmark Co.. Benchmark Co. currently has a $2.50 target price on the stock.

Riskified (NYSE:RSKD) had its overweight rating reaffirmed by analysts at Piper Sandler. Piper Sandler currently has a $7.00 price target on the stock.

Smith Micro Software (NASDAQ:SMSI) had its buy rating reaffirmed by analysts at Benchmark Co.. They currently have a $5.00 target price on the stock.

Protara Therapeutics (NASDAQ:TARA) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $23.00 target price on the stock.

Target Hospitality (NASDAQ:TH) had its market perform rating reaffirmed by analysts at Oppenheimer Holdings Inc..

Tower Semiconductor (NASDAQ:TSEM) had its buy rating reaffirmed by analysts at Benchmark Co.. The firm currently has a $55.00 price target on the stock.

Voyager Therapeutics (NASDAQ:VYGR) had its buy rating reaffirmed by analysts at Canaccord Genuity Group Inc.. Canaccord Genuity Group Inc. currently has a $14.00 target price on the stock.

Voyager Therapeutics (NASDAQ:VYGR) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $30.00 price target on the stock.

Westport Fuel Systems (NASDAQ:WPRT) (TSE:WPRT) had its sector perform rating reissued by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $8.00 target price on the stock.

WidePoint (NYSEAMERICAN:WYY) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $7.00 price target on the stock.

YETI (NYSE:YETI) had its hold rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They currently have a $44.00 target price on the stock.

Yatra Online (NASDAQ:YTRA) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $4.00 price target on the stock.